Pharmaceuticals, Biotechnology & Life Sciences

Oxford Nanopore’s Q1 earnings show narrowing losses, rising revenue and improved margins, while CEO incentives and FY27/FY28 guidance boost investor confidence.

Shenzhen Salubris Pharmaceuticals: Explore its high‑growth portfolio of tablets, capsules, and injections, market‑cap strength, and 57.96 P/E, driving future pharma innovation.

ProQR Therapeutics NV pioneers biotech solutions for rare genetic disorders, trading near $2.22 on Nasdaq with a $303 M market cap and a promise of breakthrough therapies.

Goldman Sachs raises AstraZeneca target price to £163, citing strong drug pipeline, strategic partnerships, and resilient earnings—investors should watch upcoming earnings for confirmation.

Gerresheimer AG verkauft Kunststoffverpackungen an Apax – stärkt Fokus auf Glasverpackungen für Pharma & Medizin, steigert Aktienkurs.

Hemostemix Inc. faces financial challenges despite pioneering blood‑derived cell therapies for severe medical disorders, urging investors to weigh risk vs. breakthrough potential.

BioArctic partners with Mesenkia to create a BBB‑shuttled antibody targeting glioblastoma, merging BrainTransporter™ and KITAIbodies® to tackle brain cancer’s toughest barrier.

AbbVie’s latest growth strategy: $8B bond‑backed acquisition, Wells Fargo’s bullish HS target, and new oncology pipeline, all driving a $442B valuation.

Moderna stock surges 160% after breakthrough melanoma vaccine data, sparking analyst upgrades and $4.8 billion short‑seller losses.

Oxford Nanopore narrows 2026 losses, boosts margins and pledges FY27‑28 profitability, positioning itself as a financially disciplined biotech leader.